COST EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS

被引：0
|
作者：
Kip, M. [1 ]
van den Bosch, M. [2 ,3 ]
Fischer, K. [4 ]
Tamminga, R. [5 ]
Lepage-Nefkens, I [1 ]
机构：
[1] PANAXEA, Enschede, Netherlands
[2] Bayer, Mijdrecht, Netherlands
[3] Univ Med Ctr Utrecht, Van Creveldkliniek, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[5] Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9713 AV Groningen, Netherlands
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1687
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY57
引用
收藏
页码：A531 / A531
页数：1
相关论文
共 50 条
  • [21] A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
    Jamal, Munirah
    Sathar, Jameela
    Jamari, Jamaliah
    Saffian, Shamin Mohd
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2023, 30 (01): : 129 - 136
  • [22] Recombinant factor VIII half life using a bayesian model in patients with severe haemophilia A on prophylaxis in Turkey
    Albayrak, C.
    Albayrak, D.
    HAEMOPHILIA, 2019, 25 : 64 - 64
  • [23] UKPK trial interim analysis: Use of Pharmacokinetic intervention to optimise Factor VIII prophylaxis in severe haemophilia A
    Badle, S.
    Hart, D.
    Batty, P.
    Van Os, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 131 - 131
  • [24] Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease
    Miners, AH
    Sabin, CA
    Tolley, KH
    Lee, CA
    JOURNAL OF INTERNAL MEDICINE, 1998, 244 (06) : 515 - 522
  • [25] Inversions of the factor VIII gene in Slovenian patients with severe haemophilia A
    Strmecki, L
    Benedik-Dolnicar, M
    Vidan-Jeras, B
    Komel, R
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1999, 63 (01) : 64 - 66
  • [26] Spectrum of factor VIII mutations in Arab patients with severe haemophilia A
    Abu-Amero, K. K.
    Hellani, A.
    Al-Mahed, M.
    Al-Sheikh, I.
    HAEMOPHILIA, 2008, 14 (03) : 484 - 488
  • [27] COST-EFFECTIVENESS ANALYSIS OF DIFFERENT RECOMBINANT FACTOR VIII FOR PROPHYLACTIC TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIAA IN CHINA
    Yang, L.
    Peng, J.
    Gu, C.
    Wang, Z.
    Zuo, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [28] Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
    Megias-Vericat, J. E.
    Bonanad, S.
    Haya, S.
    Cid, A. R.
    Marques, M. R.
    Monte, E.
    Perez-Alenda, S.
    Bosch, P.
    Querol, F.
    Poveda, J. L.
    THROMBOSIS RESEARCH, 2019, 174 : 151 - 162
  • [29] COST-EFFECTIVENESS OF PROPHYLAXIS COMPARED TO ON-DEMAND TREATMENT IN SEVERE HAEMOPHILIA A. SYSTEMATIC REVIEW
    Odnoletkova, I
    VALUE IN HEALTH, 2016, 19 (07) : A599 - A600
  • [30] Prophylaxis or on demand treatment for adult patients with severe haemophilia?
    Neme, Daniela
    Del Rio, Lina
    Cocca, Andrea
    Chirino, Walter
    HAEMOPHILIA, 2023, 29 : 12 - 13
12345